Cure8 research brief
This study explores a novel, non-invasive way to block IL-23 — an important inflammatory driver in IBD — by orally delivering small IL-23 inhibitors using engineered Lactococcus lactis in mouse colitis models.
Researchers and clinicians working on IBD therapeutics, mucosal immunology, and microbiome-based delivery; patients interested in upcoming non-invasive treatment approaches.
Researchers engineered Lactococcus lactis to produce small non-antibody binding proteins that target either the IL-23 p19 subunit (ILP317) or the IL-23 receptor (REX115). In two mouse colitis models (DSS and TNBS), injected soluble forms of both binders reduced disease signs. When delivered orally via recombinant L.
lactis, the ILP317-expressing bacteria showed more consistent protective effects than REX115-expressing bacteria in several experimental settings. The work is preclinical and conducted in mouse models, not humans.
‘‘Oral delivery’’ here used food pellets with engineered, non-colonizing bacteria in controlled experiments; this is an early-stage strategy that would require extensive safety and efficacy testing before clinical use.
Results are from mouse models (DSS and TNBS) and involve engineered non-colonizing bacteria and recombinant proteins; findings are preclinical and need translation, safety testing, and human trials before clinical relevance can be assessed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
Real-world registries can show how a drug performs outside clinical trials and how patients feel over time; this study aimed to track symptoms for people starting mirikizumab for ulcerative colitis.
